AmorChem, CHU de Quebec, Universite Laval deal

VC fund AmorChem partnered with the university and CHU to develop compounds to treat endometriosis and estrogen-dependent cancers. The collaborators will focus on the preclinical development of hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitors discovered by the university and CHU. AmorChem will manage the project and said it initially allocates about C$500,000 ($479,600) in funding but there is a possibility to invest up to an additional C$2 million ($1.9 million). The university and CHU will carry out the work for the two-year project, which may be extended or shortened based on results. ...